AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30376810 — intervention group
Group type: COMPARATOR
Intervention: Continuous Epidural Infusion (CEI) 6 mL/h of ropivacaine 0.2%
Number of subjects: 84
Study 30376810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PIEB and CEI)
Number of subjects: 84
Study 26772985 — intervention group
Group type: EXPERIMENTAL
Intervention: Early prophylactic levothyroxine (LT4) treatment
Number of subjects: 94
Study 26772985 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 94
Study 25444083 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (up to 16 mg/24 h)
Number of subjects: 596
Study 22095403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 44
Study 22095403 — intervention group
Group type: COMPARATOR
Intervention: Manual (non-US-guided) injection
Number of subjects: 44
Study 22095403 — intervention group
Group type: COMPARATOR
Intervention: Comparison of US-guided vs Manual injection
Number of subjects: 44
Study 20809930 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week preconditioning program with walking and hopping exercises
Number of subjects: 0
Study 20809930 — intervention group
Group type: COMPARATOR
Intervention: 9-week training program (Control group)
Number of subjects: 0
Study 17679652 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes at baseline
Number of subjects: 15245
Study 17679652 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset diabetes
Number of subjects: 15245
Study 17679652 — intervention group
Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 15245
Study 16252739 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection pressure of 30 s/mL
Number of subjects: 28
Study 16252739 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection pressure of 160 s/mL
Number of subjects: 28
Study 12014163 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% titanium tetrafluoride (0.32 MF) for 1 minute
Number of subjects: 40
Study 12014163 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat (2.26% F) for 4 minutes
Number of subjects: 40
Study 12014163 — intervention group
Group type: EXPERIMENTAL
Intervention: Elmex (1.25% F) for 4 minutes
Number of subjects: 40
Study 12014163 — intervention group
Group type: COMPARATOR
Intervention: Control group (no solution applied)
Number of subjects: 40
Study 10215284 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 59
Study 8582499 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (granulocyte colony stimulating factor)
Number of subjects: 0
Study 8582499 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 0
Study 2198308 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 2198308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 635480 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% chlorhexidine
Number of subjects: 0
Study 635480 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% silver nitrate
Number of subjects: 0
Study 635480 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 0
Study 635480 — intervention group
Group type: COMPARATOR
Intervention: 0.25% acetic acid
Number of subjects: 0
Study 31769596 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel treatment
Number of subjects: 100
Study 31134827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO) in addition to conventional treatment, 5 days per week, 60 min each, 100% oxygen at 2 standard atmospheric pressures for 12 weeks.
Number of subjects: 158
Study 31134827 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control group).
Number of subjects: 158
Study 28186838 — intervention group
Group type: EXPERIMENTAL
Intervention: Group <70 (mean dose <70.2Gy)
Number of subjects: 181
Study 28186838 — intervention group
Group type: COMPARATOR
Intervention: Group >70 (mean dose >70.2Gy)
Number of subjects: 181
Study 28186838 — intervention group
Group type: COMPARATOR
Intervention: Group >70
Number of subjects: 181
Study 28186838 — intervention group
Group type: EXPERIMENTAL
Intervention: Group <70
Number of subjects: 181
Study 26404912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 1.25 µg + Olodaterol 5 µg
Number of subjects: 233
Study 26404912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 µg + Olodaterol 5 µg
Number of subjects: 233
Study 26404912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg + Olodaterol 5 µg
Number of subjects: 233
Study 26404912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 1.25 µg + Olodaterol 10 µg
Number of subjects: 233
Study 26404912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 µg + Olodaterol 10 µg
Number of subjects: 233
Study 26404912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg + Olodaterol 10 µg
Number of subjects: 233
Study 23407406 — intervention group
Group type: EXPERIMENTAL
Intervention: KIVA
Number of subjects: 168
Study 23407406 — intervention group
Group type: COMPARATOR
Intervention: BK
Number of subjects: 168
Study 23407406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both KIVA and BK
Number of subjects: 168
Study 21495198 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of hyoscine-N-butyl bromide (HBB) rectal suppository
Number of subjects: 130
Study 21495198 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 130
Study 19054777 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone application preceding standard gonadotrophin ovarian stimulation
Number of subjects: 62
Study 19054777 — intervention group
Group type: COMPARATOR
Intervention: High-dose gonadotrophin with minidose GnRH agonist protocol
Number of subjects: 62
Study 19054777 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone application
Number of subjects: 62
Study 19054777 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone application (normal basal FSH levels)
Number of subjects: 62
Study 19054777 — intervention group
Group type: COMPARATOR
Intervention: High-dose gonadotrophin with minidose GnRH agonist protocol (normal basal FSH levels)
Number of subjects: 62
Study 17613264 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-collecting solutions with NO-scavenging compounds (hemoglobin or 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide) placed inside tubing attached to skin for 20 min
Number of subjects: 50
Study 17613264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite pretreatment of skin
Number of subjects: 50
Study 17613264 — intervention group
Group type: COMPARATOR
Intervention: Control areas (non-meridian)
Number of subjects: 50
Study 15598977 — intervention group
Group type: EXPERIMENTAL
Intervention: IM862 (5 mg intranasally every other day)
Number of subjects: 202
Study 15598977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 15598977 — intervention group
Group type: EXPERIMENTAL
Intervention: IM862
Number of subjects: 202
Study 12104081 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes before competition
Number of subjects: 60
Study 12104081 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes after competition
Number of subjects: 60
Study 12104081 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes before exercise
Number of subjects: 60
Study 12104081 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes after exercise
Number of subjects: 60
Study 12104081 — intervention group
Group type: COMPARATOR
Intervention: Sedentary individuals
Number of subjects: 60
Study 9617985 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 200 mg/day for 3 weeks
Number of subjects: 21
Study 9617985 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (single-blind) after placebo
Number of subjects: 21
Study 9617985 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (subsequent treatment)
Number of subjects: 21
Study 9617985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7925218 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 for intubation followed by an infusion controlled by closed‐loop feedback at 90% block.
Number of subjects: 60
Study 7925218 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane and N2O
Number of subjects: 60
Study 2701811 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 2701811 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Phase II trials
Number of subjects: 0
Study 2701811 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III designs
Number of subjects: 0
Study 2701811 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate sequential analysis
Number of subjects: 0
Study 2701811 — intervention group
Group type: EXPERIMENTAL
Intervention: General methods for valid calculation of confidence limits
Number of subjects: 0
Study 2701811 — intervention group
Group type: EXPERIMENTAL
Intervention: Factorial designs
Number of subjects: 0
Study 1098524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 40
Study 1098524 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg
Number of subjects: 40
Study 1098524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pseudoephedrine and triprolidine
Number of subjects: 40
Study 1098524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31229641 — intervention group
Group type: EXPERIMENTAL
Intervention: r-ATG (4.5 mg/kg)
Number of subjects: 357
Study 28965280 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (oral, once daily, dose-adjusted to body weight)
Number of subjects: 20
Study 28965280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 25962410 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 123
Study 23883378 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat 2.5 mg-maximum group
Number of subjects: 443
Study 23883378 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 443
Study 21816062 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM plus ADV
Number of subjects: 53
Study 21816062 — intervention group
Group type: COMPARATOR
Intervention: LAM alone
Number of subjects: 53
Study 19565156 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck stabilization exercises
Number of subjects: 60
Study 19565156 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy agents + isometric and stretching exercises
Number of subjects: 60
Study 19565156 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy agents
Number of subjects: 60
Study 18958903 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative drainage
Number of subjects: 100
Study 18958903 — intervention group
Group type: COMPARATOR
Intervention: No drains (Control)
Number of subjects: 100
Study 14666399 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (40 mg daily)
Number of subjects: 10
Study 14666399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11383810 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surgical lung sealant (SLS) applied intraoperatively
Number of subjects: 124
Study 11383810 — intervention group
Group type: COMPARATOR
Intervention: Standard closure without SLS
Number of subjects: 124
Study 9209013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary changes towards patterns associated with lower risk
Number of subjects: 0
Study 9209013 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene and other compounds
Number of subjects: 0
Study 8480900 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% isoflurane/66% nitrous oxide anesthesia during surgical stimulation
Number of subjects: 20
Study 8480900 — intervention group
Group type: COMPARATOR
Intervention: 0.6% isoflurane/66% nitrous oxide anesthesia without surgical stimulation
Number of subjects: 20
Study 3501252 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg body weight)
Number of subjects: 34
Study 3501252 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.15 mg/kg)
Number of subjects: 34
Study 28899827 — intervention group
Group type: EXPERIMENTAL
Intervention: Clitoral vacuum suction device (CVSD)
Number of subjects: 31
Study 28899827 — intervention group
Group type: COMPARATOR
Intervention: Vibratory stimulation (V)
Number of subjects: 31
Study 26331782 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated scoring balloon (SB)
Number of subjects: 61
Study 26331782 — intervention group
Group type: COMPARATOR
Intervention: Uncoated scoring balloon (SB)
Number of subjects: 61
Study 24232511 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic dissection
Number of subjects: 152
Study 24232511 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 152
Study 23543483 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil up to 300 mg per day (n = 19)
Number of subjects: 37
Study 23543483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 37
Study 23543483 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 37
Study 20065252 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (RS) with 20 or 24 Gy 50% isodose
Number of subjects: 30
Study 20065252 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (RS)
Number of subjects: 30
Study 18457471 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfimeprase (0.3 mg/kg)
Number of subjects: 600
Study 18457471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 17283928 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminance contrasts inherent in the disk
Number of subjects: 0
Study 17283928 — intervention group
Group type: COMPARATOR
Intervention: Luminance contrasts between adjoining areas of the background outside the disk
Number of subjects: 0
Study 12884458 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (HUMIRA)
Number of subjects: 0
Study 10970993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary beta-carotene supplementation (60 mg daily for 3 weeks)
Number of subjects: 20
Study 10970993 — intervention group
Group type: COMPARATOR
Intervention: Control group (normoglycemic subjects)
Number of subjects: 20
Study 8978957 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Penicillamine (DPA)
Number of subjects: 74
Study 8978957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 1361081 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 48
Study 1361081 — intervention group
Group type: COMPARATOR
Intervention: Piportil
Number of subjects: 48
Study 3881176 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and lomustine (DC)
Number of subjects: 51
Study 3881176 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and 5‐FU (CF)
Number of subjects: 51
Study 30221595 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of enteric-coated aspirin
Number of subjects: 19114
Study 30221595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study 27654263 — intervention group
Group type: EXPERIMENTAL
Intervention: FIGO IVB AWM only (n = 86)
Number of subjects: 634
Study 27654263 — intervention group
Group type: COMPARATOR
Intervention: FIGO IIIC (n = 308)
Number of subjects: 634
Study 27654263 — intervention group
Group type: COMPARATOR
Intervention: FIGO IV others (n = 240)
Number of subjects: 634
Study 27654263 — intervention group
Group type: COMPARATOR
Intervention: FIGO IIIC
Number of subjects: 634
Study 25758385 — intervention group
Group type: EXPERIMENTAL
Intervention: Play-reading intervention
Number of subjects: 129
Study 25758385 — intervention group
Group type: COMPARATOR
Intervention: Standard medical lecture
Number of subjects: 129
Study 22924071 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide/formoterol
Number of subjects: 22
Study 22924071 — intervention group
Group type: COMPARATOR
Intervention: Inhaled fluticasone/salmeterol
Number of subjects: 22
Study 21114387 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinocandins
Number of subjects: 1169
Study 21114387 — intervention group
Group type: COMPARATOR
Intervention: Nonechinocandins (comparator drug)
Number of subjects: 1169
Study 18534669 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (56 Gy) only (Group A, n=72)
Number of subjects: 156
Study 18534669 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with three courses of cisplatin (50 mg/m(2)), epirubicin (60 mg/m(2)), and cyclophosphamide (500 mg/m(2)) (Group B, n=84)
Number of subjects: 156
Study 18534669 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with three courses of cisplatin, epirubicin, and cyclophosphamide (Group B, n=84)
Number of subjects: 156
Study 15757614 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) supplementation
Number of subjects: 0
Study 13130389 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg)
Number of subjects: 168
Study 13130389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 10535718 — intervention group
Group type: COMPARATOR
Intervention: enalapril 10 mg
Number of subjects: 10
Study 10535718 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 5 mg
Number of subjects: 10
Study 10535718 — intervention group
Group type: COMPARATOR
Intervention: carvedilol 25 mg
Number of subjects: 10
Study 10535718 — intervention group
Group type: COMPARATOR
Intervention: celiprolol 200 mg
Number of subjects: 10
Study 10535718 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol 200 mg daily
Number of subjects: 10
Study 8671386 — intervention group
Group type: EXPERIMENTAL
Intervention: LA and NETA (n = 47)
Number of subjects: 105
Study 8671386 — intervention group
Group type: COMPARATOR
Intervention: LA alone (n = 58)
Number of subjects: 105
Study 1745340 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 0.75 mg/kg/d
Number of subjects: 93
Study 1745340 — intervention group
Group type: COMPARATOR
Intervention: Natural history controls
Number of subjects: 93
Study 1745340 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (varied dosages from 0.15 mg/kg to 0.75 mg/kg)
Number of subjects: 93
Study 1745340 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy
Number of subjects: 93
Study 6136489 — intervention group
Group type: EXPERIMENTAL
Intervention: lopirazepam (tranquillizing agent)
Number of subjects: 72
Study 6136489 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 72
Study 30760169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase treatment
Number of subjects: 601
Study 28392365 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided ERCP without fluoroscopy (EGEWF)
Number of subjects: 114
Study 28392365 — intervention group
Group type: COMPARATOR
Intervention: ERCP (standard method)
Number of subjects: 114
Study 25529590 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified WAIS-IV Symbol Search subtest (responding with 'x')
Number of subjects: 50
Study 25529590 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified WAIS-IV Block Design (all items with red surfaces facing up)
Number of subjects: 50
Study 23228119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin gel
Number of subjects: 33
Study 23228119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 21823969 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ combination therapy administered at bedtime
Number of subjects: 204
Study 21823969 — intervention group
Group type: COMPARATOR
Intervention: Valsartan/HCTZ combination therapy administered upon awakening
Number of subjects: 204
Study 21823969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment-time groups (bedtime and upon awakening)
Number of subjects: 204
Study 21823969 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime combination treatment
Number of subjects: 204
Study 19152452 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (arginine, fatty acids, nucleotides)
Number of subjects: 42
Study 19152452 — intervention group
Group type: COMPARATOR
Intervention: Normal nutrition
Number of subjects: 42
Study 19152452 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition
Number of subjects: 42
Study 17208952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive prevention programme (including physical exercise in small groups, psychosocial group activities, lectures, and home exercises)
Number of subjects: 591
Study 17208952 — intervention group
Group type: COMPARATOR
Intervention: Counselling group (control group)
Number of subjects: 591
Study 15526557 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg/daily)
Number of subjects: 24
Study 15526557 — intervention group
Group type: COMPARATOR
Intervention: Oral progesterone (200 mg/daily)
Number of subjects: 24
Study 12784831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cusp catastrophe model
Number of subjects: 94
Study 12784831 — intervention group
Group type: COMPARATOR
Intervention: Traditional linear models
Number of subjects: 94
Study 9880623 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert interpretation of sonographic films with a grading scale of severity for nephrocalcinosis
Number of subjects: 30
Study 7754079 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative recall in pairs
Number of subjects: 0
Study 7754079 — intervention group
Group type: COMPARATOR
Intervention: Individual recall
Number of subjects: 0
Study 2272708 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate therapy
Number of subjects: 41
Study 2272708 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of calcium and nifedipine
Number of subjects: 41
Study 2272708 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 41
Study 7419561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole and acetylsalicylic acid (ASA)
Number of subjects: 389
Study 7419561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole alone
Number of subjects: 389
Study 7419561 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) alone
Number of subjects: 389